Search

Tau is a protein that normally participates in the assembly and stability of microtubules. However, it can form intraneuronal hyperphosphorylated aggregates that are hallmarks of Alzheimer's disease and other neurodegenerative disorders known as tauopathies. Tau can be phosphorylated by multiple kinases at several sites. Among such kinases, the cAMP‐dependent protein kinase A (PKA) phosphorylates tau at Ser214 (pTAU‐S214), an event that was shown to reduce the pathological assembly of the protein. Given that the neuronal cAMP/PKA‐activated cascade is involved in synaptic plasticity and memory, and that cAMP‐enhancing strategies demonstrated promising therapeutic potential for the treatment of cognitive deficits, we investigated the impact of cAMP on pTAU‐S214 in N2a cells and rat hippocampal slices. Our results confirm that the activation of adenylyl cyclase increases pTAU‐S214 in both model systems and, more interestingly, this effect is mimicked by GEBR‐7b, a phosphodiesterase 4D inhibitor with proven pro‐cognitive efficacy in rodents. [ABSTRACT FROM AUTHOR]

Intraneuronal accumulation of hyperphosphorylated tau is a pathological hallmark of several neurodegenerative disorders, including Alzheimer's disease. Phosphorylation plays a crucial role in modulating the tau‐microtubule interaction and the ability of the protein to aggregate, but despite efforts during the past decades, the real identity of the kynases involved in vivo remains uncertain. Here, for the first time, we demonstrate that the cGMP‐dependent protein kinase G (PKG) phosphorylates tau in both in vitro and in vivo models. More intriguingly, we provide evidence that PKG phosphorylates tau at Ser214 but not at Ser202, a condition that could reduce the pathological aggregation of the protein shifting tau from a pro‐aggregant to a neuroprotective anti‐aggregant conformation. [ABSTRACT FROM AUTHOR]